Content in this topic
Pfizer is testing a new coronavirus antiviral that has stopped SARs-CoV-2 from replicating in the lab in humans.
To try and understand the immune response to SARS-CoV-2, including the threat of COVID reinfection, the University of Oxford will purposely infect volunteers.
In a small clinical trial, using herpes viruses modified to only infect tumors — oncolytic virus therapy — more than doubled the life expectancy of children with aggressive brain tumors.
There is currently no HIV vaccine, but a new technique which produced specific immunity cells in humans may pave the way to one.
Researchers have reverse-engineered a common children’s virus to show the spike protein, potentially leading to a new COVID vaccine for young children.
A genetic report shows that a survivor of the 2014-2016 Ebola outbreak in Guinea is likely to have begun the latest episode.
A mosquito protein that targets the viral envelope of flaviviruses, inhibiting their activity, could help doctors treat several life-threatening diseases.
Capable of causing highly lethal disease, Ebola treatment is a public health priority. A new study shows chemo drugs may do just that.
SARS-CoV-2 mutations, which cause new variants of the virus, are eluding the virus’s proofreader. New research shows why.